Ranbaxy enters into licensing pact with EPIRUS Switzerland

Ranbaxy Laboratories today inked a licensing pact with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab prescribed to treat rheumatoid arthritis (RA).

EPIRUS Switzerland GmbH is a wholly-owned subsidiary of Boston-based Epirus Biopharmaceuticals, Inc.

The product will be introduced in India and other Emerging Markets, the company said in a statement.

At present, there is no biosimilar of Infliximab approved in India, it said.

Under the terms of the agreement, EPIRUS will develop and supply the product; and upon regulatory approval, Ranbaxy will market the same in India and other emerging markets.

Commenting on the partnership, Sanjeev I Dani, Executive Vice President & Head, Global Strategy, Ranbaxy, said, "We will utilise our strong front-end capabilities in making this product available in India and other parts of the world."

Amit Munshi, President and CEO of EPIRUS said: "We are very pleased to work with Ranbaxy to register and commercialise this important medicine. Ranbaxy has the right focus and infrastructure in these markets to effectively bring this product to the market."

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Time for banks to pass on RBI rate cuts to stakeholders of the economy

    Reserve Bank of India’s decision to cut the repo rate by 25 basis points, from 7.75 to 7.50, is a move in the right direction.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Amita Sharma

IITs: Growing needs with growing numbers

In continuance of the government’s commitment to spread the reach ...

Zehra Naqvi

For the love of language

A video doing the rounds in social media these days ...

Dharmendra Khandal

‘Poop’ coffee anyone? If civets suffer, so be it

That a drink which proudly associates itself with animal poop ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture